Research programme: peptide-based cancer therapeutics - ENKAM

Drug Profile

Research programme: peptide-based cancer therapeutics - ENKAM

Alternative Names: Dekafin2; EncaminC; Inherbin3; Inherbins

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor agonists; Protein tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (Parenteral)
  • 12 Nov 2007 Preclinical trials in Solid tumours in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top